Literature DB >> 16084315

Does mixed connective tissue disease exist? Yes.

Martin Aringer1, Günter Steiner, Josef S Smolen.   

Abstract

For patients who have combined features of rheumatoid arthritis, the limited cutaneous form of systemic sclerosis, and inflammatory myopathies, the concept of mixed connective tissue disease (MCTD) often helps to predict and diagnose organ problems and to educate the patient accordingly. With high titer IgG antibodies to U1 ribonucleoprotein (U1-snRNP), this concept is supported by a specific serologic marker, and autoantibodies to U1-snRNP and to heterogeneous nuclear ribonucleoprotein (hnRNP)-A2 display MCTD specificity with regard to the recognized epitopes. In addition, the association of MCTD with HLA-DR4 distinguishes it from systemic erythematosus lupus and systemic sclerosis, and speaks to its being a disease entity, rather than a mixture of yet undifferentiated collagen vascular diseases. The authors believe that the concept is useful in daily practice and accurate in the idea that MCTD constitutes a disease entity of its own.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084315     DOI: 10.1016/j.rdc.2005.04.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  22 in total

1.  Can SLE classification rules be effectively applied to diagnose unclear SLE cases?

Authors:  A Mesa; M Fernandez; W Wu; G Narasimhan; E L Greidinger; D K Mills
Journal:  Lupus       Date:  2016-07-11       Impact factor: 2.911

Review 2.  Pediatric Mixed Connective Tissue Disease.

Authors:  Roberta A Berard; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

3.  Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Hideya Kitamura; Yumie Yamanaka; Satoshi Ikeda; Akimasa Sekine; Tomohisa Baba; Koji Okudela; Tae Iwasawa; Tamiko Takemura; Kazuyoshi Kuwano; Takashi Ogura
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease.

Authors:  A Mesa; J A Somarelli; W Wu; L Martinez; M B Blom; E L Greidinger; R J Herrera
Journal:  Lupus       Date:  2013-11       Impact factor: 2.911

5.  Following leads: connecting dysphagia to mixed connective tissue disease.

Authors:  Rita de Sousa Gameiro; Ana Isabel Alves Reis; Ana Cristina Grilo; Carla Noronha
Journal:  BMJ Case Rep       Date:  2018-03-05

6.  Juvenile diffuse systemic sclerosis/systemic lupus erythematosus overlap syndrome--a case report.

Authors:  Heng-Kuei Lin; Jiaan-Der Wang; Lin-Shien Fu
Journal:  Rheumatol Int       Date:  2011-05-01       Impact factor: 2.631

7.  Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease.

Authors:  Pal Soltesz; Daniel Bereczki; Peter Szodoray; Maria T Magyar; Henrietta Der; Istvan Csipo; Agota Hajas; Gyorgy Paragh; Gyula Szegedi; Edit Bodolay
Journal:  Arthritis Res Ther       Date:  2010-05-06       Impact factor: 5.156

8.  Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Vaidehi R Chowdhary; Floranne C Ernste; Kevin G Moder; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-10-01       Impact factor: 4.794

9.  Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report.

Authors:  Mislav Radić; Rebecca S Overbury
Journal:  BMC Rheumatol       Date:  2021-03-19

10.  High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort.

Authors:  Jessica L Record; Timothy Beukelman; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2011-08-09       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.